Publications by authors named "Theodore Logan"

Claim this Profile
N
National Evaluation of the Management of Melanoma Patients with Multiple Positive Sentinel Lymph Nodes.
Tyler P Robinson, Kristen N Kaiser, Brian Ruedinger, John Hyngstrom, Theodore F Logan

Ann Surg Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASO Visual Abstract: National Evaluation of the Management of Melanoma Patients with Multiple Positive Sentinel Lymph Nodes.
Tyler P Robinson, Kristen N Kaiser, Brian Ruedinger, John Hyngstrom, Theodore F Logan

Ann Surg Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma.
Roberto Pili, David I Quinn, Nabil Adra, Theodore Logan, Sean Colligan

Cancer Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024.
Susan M Swetter, Douglas Johnson, Mark R Albertini, Christopher A Barker, Sarah Bateni, Theodore Logan

J Natl Compr Canc Netw· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.
Jason A Chesney, Igor Puzanov, Frances A Collichio, Parminder Singh, Mohammed M Milhem, Theodore Logan

J Immunother Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Michael B Atkins, Sandra J Lee, Bartosz Chmielowski, Ahmad A Tarhini, Gary I Cohen, Theodore F Logan

J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial.
Susan Halabi, Qian Yang, Andrea Carmack, Shiqi Zhang, Wen-Chi Foo, Theodore F Logan

Kidney Cancer J· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
Andrew J Armstrong, Andrew B Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Theodore F Logan

Clin Cancer Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma.
Andrew J Armstrong, Andrew B Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Theodore F Logan

Clin Cancer Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2.
Joseph I Clark, Brendan Curti, Elizabeth J Davis, Howard Kaufman, Asim Amin, Theodore F Logan

J Investig Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.
John Timmerman, Charles Herbaux, Vincent Ribrag, Andrew D Zelenetz, Roch Houot, Theodore Logan

Am J Hematol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003.
Arkadiusz Z Dudek, Li C Liu, Shilpa Gupta, Theodore F Logan, Eric A Singer

J Clin Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
Martin H Voss, Rupal S Bhatt, Nicholas J Vogelzang, Mayer Fishman, Robert S Alter, Theodore F Logan

Cancer· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.
Ahmad A Tarhini, Paul Frankel, Christopher Ruel, Marc S Ernstoff, Timothy M Kuzel, Theodore F Logan

Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained Exceptional Response to Poly (ADP-Ribose) Polymerase Inhibition Plus Temozolomide in Metastatic Melanoma With DNA Repair Deficiency.
Patrick J Kiel, Milan Radovich, Bryan P Schneider, Theodore F Logan

JCO Precis Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.
Joseph I Clark, Jatinder Singh, Marc S Ernstoff, Christopher D Lao, Lawrence E Flaherty, Theodore F Logan

J Immunother Cancer· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
Jason Chesney, Igor Puzanov, Frances Collichio, Parminder Singh, Mohammed M Milhem, Theodore F Logan

J Clin Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM registry.
Brendan Curti, Gregory A Daniels, David F McDermott, Joseph I Clark, Howard L Kaufman, Theodore F Logan

J Immunother Cancer· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
Neil H Segal, Theodore F Logan, F Stephen Hodi, David McDermott, Ignacio Melero

Clin Cancer Res· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
Ajjai Alva, Gregory A Daniels, Michael K K Wong, Howard L Kaufman, Michael A Morse, Theodore F Logan

Cancer Immunol Immunother· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Jeffrey S Weber, Geoff Gibney, Ryan J Sullivan, Jeffrey A Sosman, Craig L Slingluff, Theodore F Logan

Lancet Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Andrew J Armstrong, Susan Halabi, Tim Eisen, Samuel Broderick, Walter M Stadler, Theodore F Logan

Lancet Oncol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
Robert J Motzer, Brian I Rini, David F McDermott, Bruce G Redman, Timothy M Kuzel, Theodore F Logan

J Clin Oncol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.
Asim Amin, Arkadiusz Z Dudek, Theodore F Logan, Raymond S Lance, Jeffrey M Holzbeierlein

J Immunother Cancer· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole-body PET/CT evaluation of tumor perfusion using generator-based 62Cu-ethylglyoxal bis(thiosemicarbazonato)copper(II): validation by direct comparison to 15O-water in metastatic renal cell carcinoma.
James W Fletcher, Theodore F Logan, Jacob A Eitel, Carla J Mathias, Yen Ng

J Nucl Med· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis